An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Spectrum Pharmaceuticals Announces Presentation of Poziotinib in Combination with KRASG12C Inhibitors at the 2021 AACR-NCI-EORTC Conference
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Spectrum Pharmaceuticals (SPPI) announced preclinical data showcasing the synergistic effects of poziotinib combined with KRAS inhibitors on KRASG12C mutant cancer cell lines. The findings, presented by Dr. Jacqulyne Robichaux at the Virtual International Conference on Molecular Targets and Cancer Therapeutics, emphasize the importance of pan-ErbB inhibition in enhancing KRASG12C inhibitor efficacy. Chief Medical Officer Francois Lebel expressed optimism about the potential clinical implications for patients with non-small cell lung cancer (NSCLC) and other solid tumors with KRAS mutations.
Positive
Preclinical data indicates that poziotinib combined with KRAS inhibitors shows a synergistic effect.
The research highlights the potential for improved treatment options for patients with KRASG12C mutations.
The presentation at a prominent conference enhances visibility and credibility of the findings.
Negative
Results from preclinical studies may not translate effectively into clinical trials.
There are inherent risks in drug development that may affect future clinical outcomes.
The effectiveness and safety of poziotinib in combination with KRAS inhibitors are yet to be validated in clinical settings.
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the presentation of preclinical data demonstrating the synergistic impact of poziotinib when combined with KRAS inhibitors in KRASG12C mutant specific cell lines. Jacqulyne Robichaux, Ph.D., Assistant Professor, University of Texas, MD Anderson Cancer Center is presenting a poster titled “Pan-ErbB inhibition enhances activity of KRASG12C inhibitors in preclinical models of KRASG12C mutant cancers” at the Virtual International Conference on Molecular Targets and Cancer Therapeutics being held October 7-10. The conference is hosted by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organization for Research and Treatment of Cancer (EORTC).
The preclinical data demonstrated that inhibition of EGFR, HER2, HER3, and HER4 signaling by the pan-ErbB inhibitor poziotinib was synergistic when combined with KRASG12C inhibitors. These results highlight the importance of HER3 and HER4 signaling, in addition to EGFR and HER2, after KRASG12C inhibition.
“We are encouraged by these promising data developed by Dr. John Heymach and the research team at MD Anderson,” said Francois Lebel, M.D., Chief Medical Officer of Spectrum Pharmaceuticals. “The in vitro findings presented by Dr. Robichaux illustrate well the importance of pan-HER inhibition blocking the over expression of HER receptors induced by KRAS inhibitors. Poziotinib is a potent clinical stage pan-HER inhibitor and may be optimally suited for this rational combination. These exciting findings warrant further evaluation in the clinic given the large number of patients with NSCLC and other solid tumors with KRASG12C mutations who could possibly benefit from such a combination.”
The poster presentation will be available for viewing by registered participants during the conference via the meeting website beginning at 9 a.m. ET on October 7, 2021. It will also be available on the Spectrum Pharmaceuticals website at: https://investor.sppirx.com/index.php/events-and-presentations.
AboutSpectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. For additional information on Spectrum Pharmaceuticals please visit www.sppirx.com.
Forward-looking statement — This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum’s business and its future, including certain company milestones, the timing and results of FDA decisions, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include, but are not limited to, the possibility that success in preclinical studies, might not translate into success in clinical trials, the possibility that the combination synergies observed in preclinical studies may yield different results when tested in clinical studies, the possibility that poziotinib’s potency in combination with KRAS inhibitors may cause unforeseen issues when tested in a clinical setting, and other unforeseen events during clinical trials which could cause delays or other adverse consequences; other uncertainties inherent in new product development; the possibility that Spectrum’s new and existing drug candidates, including poziotinib, may not ultimately prove to be safe or effective; the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs; the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail; our dependence on third parties for clinical trials, manufacturing, distribution and quality control; and other risks that are described in further detail in the company's reports filed with the Securities and Exchange Commission (SEC). The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Spectrum in general, see the risk disclosures in the Annual Report on Form 10-K of Spectrum for the year ended December 31, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Spectrum.
SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of Spectrum Pharmaceuticals, Inc and its affiliate. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.
What are the recent findings regarding poziotinib presented by Spectrum Pharmaceuticals?
Recent preclinical data revealed that poziotinib, when combined with KRAS inhibitors, demonstrates a synergistic effect in KRASG12C mutant cancers.
What is the significance of the synergy between poziotinib and KRAS inhibitors?
The synergy suggests a potential improvement in treatment efficacy for patients with KRASG12C mutant cancers, particularly non-small cell lung cancer.
Where were the findings about poziotinib presented?
The findings were presented at the Virtual International Conference on Molecular Targets and Cancer Therapeutics from October 7-10.
Who presented the data on poziotinib and KRAS inhibitors?
The data was presented by Dr. Jacqulyne Robichaux from the University of Texas, MD Anderson Cancer Center.
What are the risks associated with the preclinical findings of poziotinib?
The risks include the possibility that preclinical success may not translate into clinical success, and unforeseen issues could arise during clinical testing.
